Navigation Links
Metformin does not improve heart function in patients without diabetes
Date:3/31/2014

Although some research has suggested that metformin, a medication often used in the treatment of diabetes, may have favorable effects on ventricular (heart) function, among patients without diabetes who underwent percutaneous coronary intervention (PCI; a procedure such as stent placement used to open narrowed coronary arteries) for ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack), treatment with metformin did not result in improved ventricular function, according to a JAMA study released online to coincide with its presentation at the 2014 American College of Cardiology Scientific Sessions.

Treatment for STEMI includes immediate treatment with anticlotting medications and PCI to restore coronary blood flow. STEMI results in left ventricular dysfunction (decreased pump function) in up to 50 percent of patients, and approximately 20 percent to 40 percent of patients develop heart failure sometime after STEMI; heart failure after STEMI is associated with a 3 to 4 times higher risk of death. Left ventricular dysfunction is regarded as the strongest predictor for adverse outcome after STEMI, according to background information in the article.

Chris P. H. Lexis, M.D., of the University of Groningen, Groningen, the Netherlands, and colleagues randomly assigned 380 patients who underwent PCI for STEMI to receive metformin hydrochloride or placebo twice daily for 4 months to determine whether metformin helps preserve left ventricular function after STEMI in patients without diabetes. Left ventricular ejection fraction (a measure of how well the left ventricle of the heart pumps blood with each contraction) was assessed by magnetic resonance imaging.

Left ventricular ejection fraction 4 months after beginning the study did not differ between the metformin group (53.1 percent) and the placebo group (54.8 percent). In addition, N-terminal pro-brain natriuretic peptide level (a cardiac biomarker) was not different between the 2 groups.

Major adverse cardiac events were observed in 6 patients (3.1 percent) in the metformin group and in 2 patients (1.1 percent) in the placebo group.

"Because left ventricular function is currently regarded as the most important predictor of morbidity and mortality after STEMI, it is unlikely that metformin will have a significant effect on long-term outcome after STEMI in patients without diabetes," the authors write.

"The present findings do not support the use of metformin in this setting."


'/>"/>

Contact: Iwan C.C. van der Horst, M.D., Ph.D.
i.c.c.van.der.horst@umcg.nl
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Diabetes drug metformin with chemo and radiation may improve outcomes in lung cancer patients
2. Metformin's Anti-Cancer Properties Clarified in an Obesity Cell Model of Pancreatic Cancer
3. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin), KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) Now Available in Pharmacies in the United States
4. Metformin Wont Aid Breast Cancer Survival in Diabetics
5. Added benefit of saxagliptin/metformin combination is not proven
6. Metformin improves blood glucose levels and BMI in very obese children
7. Study: Metformin offers cardio benefits over sulfonylureas in diabetes
8. Metformin may lower cancer risk in people with Type 2 diabetes
9. Metformin Outperforms Common Class of Diabetes Drugs in Study
10. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
11. Repeated hUCB injections may improve prognosis of children with deadly inherited disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages to prevent distracted ... from Impact Teen Drivers and California Casualty. Entries from students aged 14-22 can ... totaling $15,000 will be awarded for the best peer-to-peer messages sharing solutions to ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Connecticut Dermatology ... H. Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive ... . , “It is with considerable pleasure to welcome back Dr. Kim to the ...
(Date:1/19/2017)... ... , ... Infinity® Massage Chairs announced today that Dan Grover has joined the ... Grover comes with a total of 15 years experience in consumer goods and an ... President of Direct Sales at Traeger® Wood Pellet Grills. , Grover has elevated ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of ... discussion about the benefits of fidgeting to relieve stress and anxiety. No one ... Their Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on ...
(Date:1/18/2017)... ... 18, 2017 , ... The VA Maryland Health Care System ... research project focused on multiple sclerosis (MS). Led by Christopher M. Jewell, PhD, ... the disease without compromising normal immune function that often occurs during autoimmune diseases. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... NEW YORK , January 18, 2017 ... perception of people regarding the use of cannabis both for ... not only are more Americans open to the use of ... and financial sectors. According to Arcview Market Research, the North ... 2016, up 30% from the previous year. The research projects ...
(Date:1/18/2017)... TOKYO , Jan. 18, 2017  Astellas ... , "Astellas" ) today announced its participation in ... access to non-communicable disease (NCD) prevention, diagnostics and ... with 21 other leading pharmaceutical companies and in ... Union for International Cancer Control (UICC), Astellas will ...
(Date:1/17/2017)... LONDON , Jan. 17, 2017 ... health and for the treatment of disease. The ... individual response to a therapy. The approach studies ... with their lifestyle and environment. In January 2015, ... precision medicine to all diseases with more than ...
Breaking Medicine Technology: